2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting
Yokohama, Japan 03 August 2023 - 05 August 2023
Working out heightens sexual function in men with prostate cancer
Prostate cancer treatment upends sexual function in men, but the good news is that supervised resistance and aerobic workout can counter these sexual side effects, according to a study presented at ASCO Breakthrough 2023.
Working out heightens sexual function in men with prostate cancer
29 Aug 2023
Chemo-induced nausea, vomiting? There’s a dexamethasone-free regimen for that
A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.
Chemo-induced nausea, vomiting? There’s a dexamethasone-free regimen for that
28 Aug 2023
Doxorubicin, hypertension predict lower breast cancer recurrence
Certain comorbidities such as hypertension and diabetes mellitus (DM), along with locally advanced stage at diagnosis and systemic treatment received (ie, doxorubicin), are significantly associated with tumour recurrences among patients with breast cancer, according to a study presented at the recent ASCO Breakthrough 2023.
Doxorubicin, hypertension predict lower breast cancer recurrence
21 Aug 2023
Financial aid helps improve survival of indigent patients with breast cancer
A trend towards a favourable overall (OS) and disease-free survival (DFS) at 21 months follow-up has been observed among patients with early breast cancer enrolled to a government program that grants medicines access to indigent individuals, reports a study presented at ASCO Breakthrough 2023.